Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Randomized Phase II Study of Cipterbin® or Cipterbin® in Combination With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer (MBC)

NCT01439191 is registered in ClinicalTrials.gov with Shanghai CP Guojian Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01439191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01439191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Randomized Phase II Study of Cipterbin® or Cipterbin® in Combination With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer (MBC)
Lead sponsor
Shanghai CP Guojian Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
May 31, 2007
Enrollment
109 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer